Abstract: A relief valve (60) for a liquid container, the valve comprising a substantially conical body (50) extending into the container, and tapering inwardly away from an external wall of the container, at least one air inlet passage (62) through the substantially conical body; and a flexible diaphragm (53) extending over the conical body, being attached at its outer periphery around the substantially conical body and having a central opening surrounding the substantially conical body above the air inlet passage so as to seal the air inlet passage until the pressure within the container falls below a predetermined level.

Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: A dispenser including a base unit with an actuation mechanism for dispensing liquid and a refill unit insertible into the base unit in an inverted configuration with its outlet lowermost for the supply of liquid to the base unit. The refill unit includes an annular wall projecting into the refill unit and defining an outlet from the refill unit, the annular wall being closable at its innermost end by a valve element biased onto the annular wall. The base unit includes a hollow spigot and an annular seal surrounding and spaced from the top of the spigot whereby insertion of the refill unit into the base unit causes the spigot to enter the annular wall and to lift the valve element from the annular wall to define a flow path from the refill unit, and the annular seal to seal between the spigot and the annular wall.

Abstract: A dispenser including a base unit with an actuation mechanism for dispensing liquid and a refill unit insertible into the base unit in an inverted configuration with its outlet lowermost for the supply of liquid to the base unit. The refill unit includes an annular wall projecting into the refill unit and defining an outlet from the refill unit, the annular wall being closable at its innermost end by a valve element biased onto the annular wall. The base unit includes a hollow spigot and an annular seal surrounding and spaced from the top of the spigot whereby insertion of the refill unit into the base unit causes the spigot to enter the annular wall and to lift the valve element from the annular wall to define a flow path from the refill unit, and the annular seal to seal between the spigot and the annular wall.

Abstract: Systems and methods for the creation and management of rules for the governance of revenue sharing are disclosed herein. Generally, the system and methods generate, based on a publisher's input, at least one financial term override object. The financial term override object comprises a set of rules that override a default set of rules to govern how revenue is divided between a partner and a publisher when a supplemental content object is displayed by a partner. The financial term override object is stored in a database. After storing the financial term override object, the financial term override object is associated with the publisher and the partner. A revenue shared owed to the partner is then calculated based on the override set of rules.

Abstract: A mold assembly includes a first mold, a second mold, a first locking member, a second locking member and a pushing member. The first locking member is fixed in the first mold. The first locking member includes an engaging slot. The second locking member is pivotably mounted in the second mold. The second locking member includes an engaging portion. The engaging portion is engaged in the engaging slot to latch the first mold to the second mold, and the pushing member is adapted to push the second locking member to disengage the engaging portion from the engaging slot.

Abstract: The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.

Abstract: The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

Abstract: A mold assembly includes a first mold, a second mold, a first locking member, a second locking member and a pushing member. The first locking member is fixed in the first mold. The first locking member includes an engaging slot. The second locking member is pivotably mounted in the second mold. The second locking member includes an engaging portion. The engaging portion is engaged in the engaging slot to latch the first mold to the second mold, and the pushing member is adapted to push the second locking member to disengage the engaging portion from the engaging slot.

Abstract: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.

Abstract: The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.

Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.

Abstract: A relief valve (60) for a liquid container, the valve comprising a substantially conical body (50) extending into the container, and tapering inwardly away from an external wall of the container, at least one air inlet passage (62) through the substantially conical body; and a flexible diaphragm (53) extending over the conical body, being attached at its outer periphery around the substantially conical body and having a central opening surrounding the substantially conical body above the air inlet passage so as to seal the air inlet passage until the pressure within the container falls below a predetermined level.

Abstract: A dispenser comprising a base unit (2) with an actuation mechanism for dispensing liquid and a refill unit (1) insertible into the base unit (2) in an inverted configuration with its outlet lowermost for the supply of liquid to the base unit (2), the refill unit (1) comprising an annular wall (30) projecting into the refill unit (1) and defining an outlet from the refill unit (1), the annular wall (30) being closable at its innermost end by a valve element (33) biased onto the annular wall 30), the base unit (2) comprising a hollow spigot (11) and an annular seal (14) surrounding and spaced from the top of the spigot (11) whereby insertion of the refill unit (1) into the base unit (2) causes the spigot (11) to enter the annular wall (30) and to lift the valve element (33) from the annular wall (30) to define a flow path from the refill unit (1), through at least one cut-out portion formed in the top of the spigot (11) and/or the bottom of the valve element (33) and down the hollow spigot (11), and the annular

Abstract: The present invention relates to novel Piperidine and piperazine Derivatives, pharmaceutical compositions comprising the Piperidine and piperazine Derivatives and the use of these compounds of formula (I) for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Abstract: The present invention relates to Bicyclic Pyranone Derivatives, their compositions and uses for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. Formula (I). Y is —C— when an optional and additional bond is present and Y is —CH— when an optional and additional bond is not present; Z is —O—, —NH— or —N(alkyl)- when the optional and additional bond between Y and Z Is absent, and Z Is —N— when the optional and additional bond between Y and Z is present; R1 is H1 halo or —CN; R2 is alkyl, alkenyl or -(alkyleneVcydoalkyl; t is 0 or 1; R3 is O when the optional and additional bond between Y and R3 is present, and R3 is alkyl.haloalkyl.—C(0)0R5.